Previous 10 | Next 10 |
2024-04-25 17:31:10 ET Gainers: Alphabet ( GOOGL ) +15% . Alphabet ( GOOG ) +15% . Exponent ( EXPO ) +13% . Columbia Sportswear ( COLM ) +8% . SPS Commerce ( SPSC ) +6% . Losers: Intel Corporation ( INTC )...
CAMBRIDGE, Mass., April 23, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced it will present a poster at the America...
2024-04-17 17:01:03 ET Gainers: Vanda Pharmaceuticals ( VNDA ) +7% . Sutro Biopharma ( STRO ) +5% . CureVac ( CVAC ) +5% . CorMedix ( CRMD ) +4% . Bank OZK ( OZK ) +4% . Losers: Omega Therapeutics ( OM...
2024-04-16 16:47:42 ET More on Omega Therapeutics Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy' Seeking Alpha’s Quant Rating on Omega Therapeutics Historical earnings data for Omega Therapeutics Financial information for Omega The...
MYC-directed epigenomic controller exerts anti-tumor effect in preclinical models of EGFR inhibitor-resistant NSCLC regardless of underlying resistance mechanism Validation of novel translational assay enables detection and quantification of site-specific DNA methylation from liquid biops...
2024-04-03 08:00:08 ET Edward Tenthoff from Piper Sandler issued a price target of $9.00 for OMGA on 2024-04-03 06:48:00. The adjusted price target was set to $9.00. At the time of the announcement, OMGA was trading at $3.01. The overall price target consensus is at $9.0...
2024-03-31 06:22:14 ET Summary Omega Therapeutics is a biotech company focused on developing programmable epigenomic mRNA medicines to control gene manifestation. The company's platform has applications in various diseases, including hepatocellular carcinoma, non-small cell lung c...
2024-03-28 14:56:38 ET More on Omega Therapeutics Omega Therapeutics: The Next Weight Loss Drug Runner Omega Therapeutics: Starting 2024 With A Bang Novo Nordisk signs research deals on cardiometabolic diseases Seeking Alpha’s Quant Rating on Omega The...
Advanced OTX-2002 in MYCHELANGELO™ I trial; initial cohorts demonstrated encouraging disease control rate in late-stage HCC patients Established a research collaboration with Novo Nordisk to develop an epigenomic controller for obesity, expanding the pipeline into the cardiometab...
Cano Health Inc. Class A (CANOQ) is expected to report for Q4 2023 Cathay Pacific Airways Ltd. ADR (CPCAY) is expected to report for Q4 2023 NeuroSense Therapeutics Ltd. (NRSN) is expected to report for quarter end 2023-12-31 Bayerische Motoren Werke AG (BAMXF) is expected to report f...
News, Short Squeeze, Breakout and More Instantly...
Omega Therapeutics Inc. Company Name:
OMGA Stock Symbol:
NASDAQ Market:
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pion...
CAMBRIDGE, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced that management will participate in fires...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (NASDAQ:OMGA) ("Omega"), a clinical-stage biotechnology company pion...